Brain metastases are common secondary complications of other types of cancer, particularly lung, breast and skin cancer. The body's own immune response in the brain is rendered powerless in the fight against these metastases ...
Sep 25, 2012
0
0
A Massachusetts General Hospital research team has identified factors that contribute to solid stress within tumors, suggesting possible ways to alleviate it, and has developed a simple way to measure such pressures.
Sep 20, 2012
0
0
Researchers at Moffitt Cancer Center and colleagues have discovered that changes in the physical characteristics of the effector memory regulatory T cell can predict the progression risk of myelodysplastic syndromes (MDS) ...
Sep 13, 2012
0
0
Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research ...
Sep 10, 2012
0
0
(Medical Xpress)—Research from Karolinska Institutet shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common ...
Sep 5, 2012
0
0
Novartis AG and Incyte Corp. said Tuesday that European Union regulators approved their blood cancer drug Jakavi.
Sep 4, 2012
0
0
Hospitals can dramatically reduce the number of life-threatening central line infections in pediatric cancer patients by following a set of basic precautions, by encouraging families to speak up when they observe noncompliance ...
Sep 3, 2012
0
0
A glass a day of grapefruit juice lets patients derive the same benefits from an anti-cancer drug as they would get from more than three times as much of the drug by itself, according to a new clinical trial. The combination ...
Aug 7, 2012
0
0
Small but significant breakthrough studies on people who have been able to overcome or control HIV were presented Thursday at a major world conference on ways to stem the three-decade-old disease.
Jul 26, 2012
0
0
(Medical Xpress) -- Researchers from ETH Zurich have developed a procedure to test the clinical benefits of cancer biomarkers. The method could radically shorten the path from the lab to their application.
Jul 19, 2012
0
0
